SecBot SecBot
6-K ·Filed Jun 25, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001648257-26-000041
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should watch for ESMO presentation on July 4, 2026, and any updates on NMPA approval timeline. Given priority review status, approval could come in H2 2026. The 42.5% ORR in a heavily pretreated population is clinically meaningful and supports a differentiated profile vs. existing FGFR inhibitors.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.29
T+0 close · Jun 25, 2026 · via day close
Latest settled
+32.85%
T+60 · $13.67
Vs SPY
+29.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $10.29entry
  2. T+1 · 5mo ago −1.17%α −0.44% · $10.17
  3. T+5 · 5mo ago +4.76%α +3.20% · $10.78
  4. T+20 · 4mo ago +6.51%α +5.98% · $10.96
  5. T+60 · 8w ago +32.85%α +29.12% · $13.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED reported pivotal Phase II data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma, showing a 42.5% ORR (primary endpoint met) and a manageable safety profile. The NDA has already been accepted with priority review by China's NMPA since December 2025, de-risking the regulatory path. This is a clear positive catalyst for a mid-cap biotech with an 88% bullish analyst consensus.

Key Facts

  • Phase II registration trial (NCT04353375) met primary endpoint: IRC-assessed ORR of 42.5% (95% CI: 30.0%-53.6%)
  • Median progression-free survival (PFS) of 6.9 months; median overall survival (OS) of 16.6 months
  • Disease control rate (DCR) of 83.9% (95% CI: 74.5%-90.9%)
  • NDA for fanregratinib in advanced ICC accepted and granted priority review by China NMPA in December 2025
  • Fanregratinib is wholly owned by HUTCHMED worldwide with no out-licensed ex-China rights
  • Treatment discontinuation due to drug-related AEs limited to 2.2%; no treatment-related deaths
  • Data presented at ESMO Gastrointestinal Cancers Congress (July 2026) in a rapid oral session

Financial Impact

Fanregratinib targets a defined biomarker (FGFR2 fusion) in ICC, where approved FGFR inhibitors (Pemigatinib, Infigatinib) have shown similar sales trajectories (~$200-400M peak for second-to-market FGFR drugs). HUTCHMED retains global rights, but near-term revenues (ex-China partnership potential or China launch) are not quantifiable from this filing.

pipeline valuerevenueregulatory catalyst

Risk Factors

  • Fanregratinib is not yet approved in any jurisdiction; NMPA priority review is no guarantee of approval
  • Grade ≥3 AE rate of 48.3% is notable, though discontinuation rate is low (2.2%)
  • Commercial success depends on pricing/reimbursement in China and potential ex-China partnership terms

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000041
Document: hcm-20260625x6k.htm0001648257-26-000041
Document: 0001648257-26-000041-index-headers.html0001648257-26-000041
Document: 0001648257-26-000041-index.html0001648257-26-000041
Document: 0001648257-26-000041.txt0001648257-26-000041

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 25, 2026